Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline clearance, may reverse P-gp–mediated resistance in acute myeloid leukemia without increased toxicity. A total of 449 adults older than 60 years with acute myeloid leukemia or high-risk myelodysplastic syndrome enro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cripe, Larry D., Uno, Hajime, Paietta, Elisabeth M., Litzow, Mark R., Ketterling, Rhett P., Bennett, John M., Rowe, Jacob M., Lazarus, Hillard M., Luger, Selina, Tallman, Martin S.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2010
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993615/
https://ncbi.nlm.nih.gov/pubmed/20716770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-277269
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares